Research programme: immune disorder therapeutics - Lycera

Drug Profile

Research programme: immune disorder therapeutics - Lycera

Alternative Names: Bz-423; LYC-53976

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lycera
  • Class Antifibrotics; Immunotherapies; Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors; Adenosine triphosphatase modulators; Helper-inducer T-lymphocyte inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis; Inflammatory bowel diseases
  • No development reported Autoimmune disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
  • 09 Jun 2015 Lycera and Celgene agree to co-develop rho-associated kinase inhibitors worldwide
  • 09 Jun 2015 Preclinical trials in Fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top